Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection Clinical Trial

Official title:
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine (RSV 6120/∆NS2/1030s) in RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age.

Clinical Trial Description

This study will evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated RSV vaccine (RSV 6120/∆NS2/1030s) in RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age. The vaccine will be evaluated in a stepwise fashion beginning in RSV-seropositive children (Group 1), and then in RSV-seronegative infants and children (Group 2). In each group, participants will be randomly assigned to receive a single dose of RSV 6120/∆NS2/1030s vaccine or placebo at study entry (Day 0). Participants will be enrolled in the study between April 1 and October 31, outside of the RSV season. Group 1 (RSV-seropositive children) will be followed for 28 days. Group 2 (RSV-seronegative infants and children) will remain on study until they complete the post-RSV season visit. Group 2 participants may participate in an optional second season of RSV surveillance during November to March of the second year following enrollment. Study visits for all participants may include clinical assessments, blood collection, and nasal washes. Additionally, participants' parents or guardians will be contacted by study staff at various times during the study to monitor participants' health. ;

Study Design

Related Conditions & MeSH terms

Respiratory Syncytial Virus Infections
RSV Infection

Clinical Trial Details

NCT number	NCT03387137
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 1
Start date	October 13, 2017
Completion date	May 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03698084` - RESCEU: Defining the Burden of RSV Disease
Recruiting	`NCT05550545` - Infant RSV Infections and Health-related Quality of Life of Families
Completed	`NCT05587478` - A Study of EDP-323 in Healthy Subjects	Phase 1
Recruiting	`NCT06180993` - Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Suspended	`NCT03909867` - Emission Patterns of Respiratory Syncytial Virus
Recruiting	`NCT06259487` - Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.	N/A
Not yet recruiting	`NCT04144816` - Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
Completed	`NCT01090557` - Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study	N/A
Terminated	`NCT01475305` - Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)	Phase 1
Not yet recruiting	`NCT05928507` - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed	`NCT03062917` - Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis	N/A
Completed	`NCT03691623` - A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model	Phase 2
Completed	`NCT05070975` - Severity of RSV Infections in Twins
Active, not recruiting	`NCT04938830` - Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)	Phase 3
Recruiting	`NCT05568706` - A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.	Phase 2
Completed	`NCT03755778` - Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects	Phase 1
Completed	`NCT01483911` - ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers	Phase 1
Recruiting	`NCT06170242` - A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model	Phase 2
Completed	`NCT03750383` - Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects	Phase 1
Completed	`NCT05118386` - Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.